Earnings Releases·Nov 4, 2026, 4:10 PM ET

Vir Biotechnology — Third Quarter 2026 Earnings Summary

Net loss narrowed to $96.3 million ($0.57 per share) from $163.1 million ($1.17 per share) in Q3 2025, driven by a $75.0 million non-recurring milestone expense in the prior year that reduced R&D expenses to $80.0 million; total revenues were negative $188,000 compared to $240,000 previously.
Cash, cash equivalents, and investments totaled $901.3 million as of September 30, 2026, with management stating these funds will support operations into the second half of 2028.
Key clinical milestones include expected topline data from the Phase 3 ECLIPSE 1 trial for chronic hepatitis delta in Q4 2026, with ECLIPSE 2 and 3 data anticipated in Q1 2027, while pivotal oncology trials for VIR-5500 are scheduled to begin in 2027.
Strategic progress includes the FDA Fast Track designation for VIR-5500 in metastatic castration-resistant prostate cancer, ongoing Phase 1 trials for VIR-5818 and VIR-5525, and a new Gilead collaboration to develop three novel T-cell engagers with up to $1.74 billion in potential milestones.
Leadership changes include the appointments of Aziz Sawaf as CFO and David Liu as CMO, alongside the addition of Suzanne Topalian to the Board of Directors.